[go: up one dir, main page]

SV2008002466A - Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh - Google Patents

Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh

Info

Publication number
SV2008002466A
SV2008002466A SV2006002466A SV2006002466A SV2008002466A SV 2008002466 A SV2008002466 A SV 2008002466A SV 2006002466 A SV2006002466 A SV 2006002466A SV 2006002466 A SV2006002466 A SV 2006002466A SV 2008002466 A SV2008002466 A SV 2008002466A
Authority
SV
El Salvador
Prior art keywords
steroid hormones
oblea
ref
blood
application system
Prior art date
Application number
SV2006002466A
Other languages
English (en)
Inventor
Markus Krume
Sascha General
Albert Radlmaier
Michael Dittgen
Keith Jensen
Original Assignee
Lts Lohmann Therapie Systeme Ag
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36998911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2008002466(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lts Lohmann Therapie Systeme Ag, Schering Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of SV2008002466A publication Critical patent/SV2008002466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA COMO UN SISTEMA EN FORMA DE PELÍCULA PARA LA ADMINISTRACIÓN TRANSMUCOSA DE HORMONAS ESTEROIDES. SE DIVULGA UN SISTEMA DE APLICACIÓN QUE SE DISUELVE EN LA CAVIDAD BUCAL PARA HORMONAS ESTEROIDES QUE SE LIBERA CON UNA ELEVADA BIODISPONIBILIDAD. EL SISTEMA DE APLICACIÓN EN FORMA DE PELÍCULA SE DISUELVE EN LA CAVIDAD BUCAL, CON PREFERENCIA, EN UN PERÍODO DE MENOS DE 30 MIN, EN DONDE LA HORMONA ESTEROIDE DEL SISTEMA DE APLICACIÓN QUE PENETRA POR VÍA TRANSMUCOSA EN LA CIRCULACIÓN SANGUÍNEA PRODUCE UN RÁPIDO AUMENTO DE LA CONCENTRACIÓN EN LA SANGRE. ASÍ SE PUEDE LOGRAR UN MÁXIMO DE LA CONCENTRACIÓN DE ESTA HORMONA ESTEROIDE EN SANGRE EN UN PERIODO DE MENOS DE 60 MIN DESPUÉS DE LA APLICACIÓN
SV2006002466A 2005-03-31 2006-03-27 Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh SV2008002466A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005015128A DE102005015128B4 (de) 2005-03-31 2005-03-31 Wafer enthaltend Steroidhormone

Publications (1)

Publication Number Publication Date
SV2008002466A true SV2008002466A (es) 2008-02-08

Family

ID=36998911

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002466A SV2008002466A (es) 2005-03-31 2006-03-27 Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh

Country Status (26)

Country Link
US (2) US9763960B2 (es)
EP (1) EP1863444B1 (es)
JP (2) JP5843416B2 (es)
KR (2) KR20140063740A (es)
CN (2) CN104983669B (es)
AR (1) AR054245A1 (es)
AU (1) AU2006228820B2 (es)
BR (1) BRPI0609601A2 (es)
CA (1) CA2598892C (es)
CR (1) CR9468A (es)
DE (1) DE102005015128B4 (es)
DO (1) DOP2006000070A (es)
EA (1) EA014183B1 (es)
GT (1) GT200600126A (es)
IL (1) IL186081A0 (es)
MX (1) MX2007012081A (es)
NO (1) NO20075404L (es)
NZ (1) NZ592882A (es)
PE (1) PE20061194A1 (es)
SG (1) SG179459A1 (es)
SV (1) SV2008002466A (es)
TW (1) TWI393576B (es)
UA (1) UA92011C2 (es)
UY (1) UY29441A1 (es)
WO (1) WO2006102990A2 (es)
ZA (1) ZA200706116B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2623206C2 (ru) 2005-04-15 2017-06-22 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
EP2252261A2 (en) * 2008-02-13 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
MX2010008940A (es) * 2008-02-13 2010-10-05 Bayer Schering Pharma Ag Sistemas de administracion de drogas que contienen estradiol.
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
US20120282340A1 (en) * 2008-11-21 2012-11-08 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
US10744086B2 (en) 2009-10-30 2020-08-18 Ix Biopharma Ltd. Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
US9822257B2 (en) 2012-07-23 2017-11-21 Crayola Llc Dissolvable films and methods of using the same
DE102017112527B4 (de) * 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
WO2019152854A1 (en) * 2018-02-02 2019-08-08 Aytu Bioscience, Inc. Methods of testosterone therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
WO1993023011A1 (en) * 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19847252B4 (de) * 1998-10-02 2004-02-12 Jenapharm Gmbh & Co. Kg Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
CA2415082A1 (en) * 2000-07-06 2002-01-17 Delsys Pharmaceutical Corporation Method for formulating healthcare products with enhanced stability
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
WO2005011617A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
MXPA06003316A (es) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.

Also Published As

Publication number Publication date
CN104983669A (zh) 2015-10-21
AU2006228820A1 (en) 2006-10-05
EP1863444B1 (de) 2015-12-09
TW200714299A (en) 2007-04-16
EP1863444A2 (de) 2007-12-12
NZ592882A (en) 2012-12-21
EA200702102A1 (ru) 2008-04-28
DE102005015128A1 (de) 2006-10-05
UA92011C2 (ru) 2010-09-27
IL186081A0 (en) 2008-01-20
CA2598892C (en) 2014-10-14
CN101132766A (zh) 2008-02-27
MX2007012081A (es) 2007-11-21
WO2006102990A2 (de) 2006-10-05
GT200600126A (es) 2007-03-14
CA2598892A1 (en) 2006-10-05
AR054245A1 (es) 2007-06-13
CR9468A (es) 2008-01-21
ZA200706116B (en) 2008-11-26
TWI393576B (zh) 2013-04-21
KR20080002798A (ko) 2008-01-04
CN104983669B (zh) 2018-05-18
UY29441A1 (es) 2006-10-31
US20060222708A1 (en) 2006-10-05
KR20140063740A (ko) 2014-05-27
JP2013155190A (ja) 2013-08-15
BRPI0609601A2 (pt) 2010-04-20
SG179459A1 (en) 2012-04-27
JP5843416B2 (ja) 2016-01-13
JP2008534533A (ja) 2008-08-28
AU2006228820B2 (en) 2011-08-25
US20170348321A1 (en) 2017-12-07
DOP2006000070A (es) 2007-08-15
KR101428625B1 (ko) 2014-08-13
WO2006102990A3 (de) 2007-03-22
US9763960B2 (en) 2017-09-19
EA014183B1 (ru) 2010-10-29
PE20061194A1 (es) 2006-11-23
DE102005015128B4 (de) 2008-12-11
NO20075404L (no) 2007-12-20

Similar Documents

Publication Publication Date Title
SV2008002466A (es) Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
AR033418A1 (es) Preparado farmaceutico mucoadhesivo desintegrable para la administracion de sustancia activa en medicina veterinaria y humana
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
BRPI0416370A (pt) sistema de distribuição de liberação controlada para aplicações nasais
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
CO6290631A2 (es) Composición oral que contiene amino ácidos y un agente blanqueador
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
PE20030519A1 (es) Forma de dosificacion, dispositivo y metodos de tratamiento
PE20211492A1 (es) Composiciones estables de semaglutida y usos de las mismas
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
ATE507818T1 (de) Orale verabreichung eines calcitonins
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
AR065564A1 (es) Composiciones farmaceuticas que comprenden un agente calciletico
AR075082A1 (es) Utilizacion de vitamina e o sus derivados para el control de artropodos
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
CR10407A (es) Formulacion de medicamento liquida.
AR056500A1 (es) Metodo para preparar una composicion medica
UY31097A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
PE20081573A1 (es) Composiciones y metodos para tratar las convulsiones
SV2007002235A (es) Nuevos derivados de pirimidina y su uso ref. bhc041311-sv
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.

Legal Events

Date Code Title Description
FG Grant
FD Lapse